Patient-Reported Outcomes in Patients with Chronic Migraine Receiving Placebo or Erenumab (AMG 334) in a Phase 2, Randomized, Double-Blind Study

被引：0
|
作者：
Tepper, Stewart [1 ]
Lipton, Richard [2 ]
Reuter, Uwe [3 ]
Silberstein, Stephen [4 ]
Stewart, Walter [5 ]
Leonardi, Dean [6 ]
Desai, Pooja [7 ]
Cheng, Sunfa [8 ]
Mikol, Dan [8 ]
Lenz, Robert [8 ]
机构：
[1] Geisel Sch Med Dartmouth, Hanover, NH USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY USA
[3] Charlie Univ Med Berlin, Dept Neurol, Berlin, Germany
[4] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA USA
[5] Sutter Hlth, Walnut Creek, CA USA
[6] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA USA
[7] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA USA
[8] Amgen Inc, Global Dev, Thousand Oaks, CA USA
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.167
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Patient-Reported Outcomes in Chronic Migraine Patients with Prior Prophylactic Treatment Failure Receiving Placebo or Erenumab: Subgroup Analysis of a Pivotal Randomised Study
    Lanteri-Minet, M.
    Buse, D.
    Starling, A. J.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Cheng, S.
    Klatt, J.
    Mikol, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 409 - 409
  • [22] PATIENT-REPORTED OUTCOMES IN CHRONIC MIGRAINE PATIENTS WITH PRIOR PROPHYLACTIC TREATMENT FAILURE RECEIVING PLACEBO OR ERENUMAB: SUBGROUP ANALYSIS OF A PIVOTAL RANDOMISED STUDY
    Lanteri-Minet, M.
    Buse, D. C.
    Starling, A.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Cheng, S.
    Klatt, J.
    Mikol, D. D.
    CEPHALALGIA, 2018, 38 : 49 - 50
  • [23] PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN MIGRAINE PREVENTION: PRIMARY RESULTS OF THE STRIVE TRIAL
    Goadsby, Peter J.
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [24] Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: Primary results of the STRIVE trial
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel D.
    Lenz, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [25] Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials
    Dinan, Michaela A.
    Compton, Kate L.
    Dhillon, Jatinder K.
    Hammill, Bradley G.
    DeWitt, Esi Morgan
    Weinfurt, Kevin P.
    Schulman, Kevin A.
    MEDICAL CARE, 2011, 49 (04) : 415 - 419
  • [26] Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
    Lipton, Richard B.
    Pozo-Rosich, Patricia
    Blumenfeld, Andrew M.
    Li, Ye
    Severt, Lawrence
    Stokes, Jonathan T.
    Creutz, Lela
    Gandhi, Pranav
    Dodick, David
    NEUROLOGY, 2023, 100 (08) : E764 - E777
  • [27] Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
    Sun, Hong
    Dodick, David W.
    Silberstein, Stephen
    Goadsby, Peter J.
    Reuter, Uwe
    Ashina, Messoud
    Saper, Joel
    Cady, Roger
    Chon, Yun
    Dietrich, Julie
    Lenz, Robert
    LANCET NEUROLOGY, 2016, 15 (04): : 382 - 390
  • [28] Single-Dose and Multiple Dose, Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies of AMG 334 in Healthy Subjects and Migraine Patients
    de Hoon, J. N.
    Van Hecken, A.
    Yan, L.
    Smith, B.
    Chen, J.
    Bautista, E.
    Hamilton, L.
    Waksman, J.
    Vu, T.
    Vargas, G.
    HEADACHE, 2015, 55 : 174 - 175
  • [29] Results of the Open-Label Extension of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of AMG 334 for the Prevention of Episodic Migraine
    Sun, Hong
    Dodick, David W.
    Goadsby, Peter
    Silberstein, Stephen
    Reuters, Uwe
    Ashina, Messoud
    Saper, Joel R.
    Cady, Roger
    Zhang, Feng
    Trotman, Marie-Louise
    Dietrich, Julie
    Lenz, Robert
    HEADACHE, 2015, 55 : 256 - 257
  • [30] Phase 1, randomized, double-blind, placebo-controlled, single-dose and multiple dose studies of AMG334 in healthy subjects and migraine patients
    de Hoon, J.
    van Hecken, A.
    Yan, L.
    Smith, B.
    Chen, J.
    Bautista, E.
    Hamilton, L.
    Waksman, J.
    Vu, T.
    Vargas, G.
    CEPHALALGIA, 2015, 35 : 45 - 46
12345